There are however, a number of alternative or complementary avenues for further exploration of combination treatments that may improve regime efficacy, including targeting TIM-3 and Lag-3, additional co-inhibitory receptors known to be clinically significant in lung cancer escape from immune control (41) or inhibition of TReg (42) and MDSC suppressive cells (43) within the developing TME. The gene discussed is HAVCR2; the disease is lung carcinoma.